CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Metoprolol Tartrate Oral Tablet +2 moredrug
Likely dose
Metoprolol Tartrate Oral Tablet 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03008382
NCT03008382Phase 4Completed
CompareCT.gov

Interstitial Cystitis: Examination of the Central Autonomic Network

Virginia Commonwealth University·interventional·Posted Jan 2, 2017·Updated Feb 17, 2025

In Brief

A Phase 4 clinical trial evaluating Metoprolol Tartrate Oral Tablet, Placebo Oral Tablet, and 1 other intervention for Interstitial Cystitis/Painful Bladder Syndrome and Myofascial Pelvic Pain. Completed, enrolled 72 participants across 2 sites.

Detailed Summary

This proposal aims to move the science of chronic pelvic pain (CPP) from simple associations towards an investigation of cause and effect relationships. The investigators will determine whether the striking changes in autonomic nervous system responsiveness (ANS-R) contribute meaningfully to the pathogenesis of CPP.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInterstitial Cystitis/Painful Bladder Syndrome, Myofascial Pelvic Pain
CountriesUnited States
CollaboratorsEndeavor Health, Case Western Reserve University

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2, 2017
Enrollment StartMar 1, 2017
Primary CompletionMar 16, 2022
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.5 years ago

Interventions

Metoprolol Tartrate Oral Tabletdrug

Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.

Placebo Oral Tabletdrug

Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.

No intervention- observational sub-studyother

Participants did not receive placebo or metoprolol during the entire duration of the study.